focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksProteome Share News (PRM)

Share Price Information for Proteome (PRM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 3.80
Bid: 3.50
Ask: 4.50
Change: 0.49 (13.96%)
Spread: 1.00 (28.571%)
Open: 3.80
High: 3.80
Low: 3.80
Prev. Close: 3.51
PRM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Proteome Appoints Geoffrey Ellis As Finance Director, Loss Widens

Tue, 30th Sep 2014 09:41

LONDON (Alliance News) - Proteome Sciences PLC said Tuesday that has appointed Geoffrey Ellis as Finance Director, and posted a slightly widened pretax loss for the half-year to the end of June.

Ellis previously acted as chief financial officer of The Walt Disney Co's Network of Disney Channels in Europe, the Middle East and Africa, and managing director Disney Channel Scandinavia, Middle East and Emerging Markets.

Ellis succeeds James Malthouse, who is retiring after 20 years with the company.

Proteome posted a pretax loss of GBP2.1 million, widened from a loss of GBP1.9 million a year before, as revenue declined to GBP784,276 from GBP885,475, and administrative expenses rose slightly to GBP2.5 million from GBP2.3 million.

The company said following the growth in licensing, services and sales of its Tandem Mass Tag reagents in 2013, its core technologies had continued to strengthen in the first-half of 2014. Some contracts it was expecting were delayed, however, and the company said because of their size it is difficult to predict when they will come through.

Proteome said that whilst it is "difficult to be precise" over the timing of these revenue contributions, the scale and number of contracts in its order book is "growing steady and that performance is expected to continue in 2015."

Sales of Tandem Mass Tag reagent's rose 98% compared to the previous year. Proteome expects to see a more significant contribution from the products in the second-half, as well as continued improvement in its revenues from licences, sales and services.

Last Friday the company announced "excellent" results from in vitro toxicity tests for its two lead compounds to treat Alzheimer's disease, which it hopes will attract pharmaceutical companies to partner with Proteome on the treatments.

Shares in Proteome are trading down 8.0% at 35.18 pence Tuesday morning.

By Hana Stewart-Smith; hanassmith@alliancenews.com; @HanaSSAllNews

Copyright 2014 Alliance News Limited. All Rights Reserved.

More News
20 Nov 2013 07:52

AIM IN BRIEF: Rangers FC Appoints Graham Wallace As CEO

Read more
30 Sep 2013 09:26

Proteome Sciences Losses Widen Despite Revenue Growth; Signs USD2.1M Contract

Read more
18 Sep 2013 15:03

Proteome Expects Strong Second-Half Growth After Making Alzheimer's Progress

Read more
12 Jun 2013 11:37

Proteome Sciences to develop cancer pathway profiling assays

AIM-listed biotech group Proteome Sciences has unveiled its largest contract to date comprising a technology agreement with Thermo Fisher Scientific, to develop advanced methods to profile changes in cancer pathways. Proteome Sciences said that the contract - which it valued at £2.1m - would prov

Read more
18 Mar 2013 14:29

Proteome Sciences looks ahead with confidence

Drug developer Proteome Sciences has told investors that it expects strong revenue growth across the company's three main divisions in 2013 and said it is 'much encouraged by the prospects'. The announcement comes after the group received a positive response to the presentation of four posters tha

Read more
31 Dec 2012 12:50

STOCKS NEWS EUROPE-UK small caps closes modestly higher

The FTSE Small Caps index closes 0.1 percent higher on Monday, New Year's Eve, tracking similar modest gains by the mid caps, also up 0.1 percent, while the blue chips shed 0.5 percent after a half-day session. The small caps index has gained 24 percent over 2012, just outperforming a 22 percent adv

Read more
31 Dec 2012 10:48

Proteome delivers encouraging results from Alzheimers study

Drug maker Proteome Sciences has completed the in-vivo study of its CK1D inhibitor programme in Alzheimer's disease on time, with the results showing that both of the lead compounds for CK1D demonstrated improved cognitive function. The firm said the results provide important in-vivo proof of prin

Read more
28 Sep 2012 10:46

Proteome Sciences narrows losses, bright outlook

Proteomics specialist Proteome Sciences reduced half year losses and expects second half revenues to be significantly boosted as it doubles the number of biomarker tests available from PS Biomarker Services. The group expects major licences and contracts from its proprietary biomarkers and services

Read more
18 Sep 2012 10:57

Proteome stroke test could save thousands from brain damage

Medical technology group Proteome Sciences has released details of a study into a blood test which could reduce brain damage in thousands of stroke victims. The group has been collaborating with researchers at the University of Geneva to produce the test which can tell how long ago a stroke actuall

Read more
20 Aug 2012 07:43

London pre-open: Doubts about further Chinese stimulus

City sources predict the FTSE 100 will open up five points from Friday's close of 5,852, having gained 18 points during Friday's session following positive data from the US. Over the weekend it was reported in Europe by the Handelsblatt newspaper that the European Union could appoint the European

Read more
20 Aug 2012 07:20

Proteome Sciences reports collaboration research agreement

Biotech group Proteome Sciences has agreed to work with CHDI Foundation Inc on a systems biology project regarding Huntington's disease. Initially, Proteome will provide its PS Biomarker Services protein profiling to CHDI's research programmes. The analyses will be performed at Proteome's facility

Read more
5 Apr 2012 11:50

Proteome issues new licence for stroke product

Pharma group Proteome Sciences has granted a non-exclusive licence to UK firm Randox Laboratories for its portfolio of stroke biomarkers. Under the terms of the agreement Randox will develop products for early diagnosis of stroke and subsequent monitoring of treatment outcomes. Proteome will ear

Read more
28 Mar 2012 10:46

Proteome rockets on Alzheimer's blood test

Pharma group Proteome Sciences has had a strong morning on the markets after announcing success in its project to develop better diagnostic tools for Alzheimer's disease. A study of 1,000 patients has shown three distinct "biomarkers" in people's blood which can discriminate between mild "cognitive

Read more
19 Mar 2012 10:17

Stroke consortium to get €11m grant

Shares in biomarker specialist Proteome Sciences rose almost 5% on Monday morning after it announced the EU was to award €11m to a consortium of which it is a member. Euro-HYP-1, a consortium of academic, clinical and industrial European partners that includes Proteome, has been awarded the grant f

Read more
27 May 2011 12:09

Proteome boosted by Sanofi settlement

Biomarker specialist Proteome Sciences is back in profit after receiving €11m from Sanofi-Aventis to settle a warranty claim. The company posted pre-tax profits of £4.59m in the year to the end of December, including the warranty claim. This compared £4.20m pre-tax loss in 2009. Revenues for 2010

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.